跳至主要内容
临床试验/NCT07502456
NCT07502456招募中不适用

Clareon TruPlus Single-Arm Study

Alcon Research5 个研究点 分布在 1 个国家目标入组 122 人开始时间: 2026年5月26日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
122
试验地点
5
主要终点
Mean Binocular Photopic Best Corrected Distance Visual Acuity (BCDVA)

研究概览

简要总结

The purpose of this research study is to generate safety and performance data for Clareon TruPlus Monofocal Intraocular Lenses (IOLs). IOLs are medical devices that are implanted in the eye during cataract surgery to restore clear vision after the cloudy natural lens has been removed. IOLs are intended to remain in the eyes for the duration of the patient's lifetime.

详细描述

In this study, subjects will be implanted with Clareon TruPlus Monofocal IOLs. The IOL to be implanted (Non-Toric or Toric) will be based on the recommendation of an IOL calculator.

Subjects will attend 8 study visits, including one preoperative visit, two surgical visits, and five postoperative visits. The second eye surgery will occur 0-14 days after the first eye surgery. The total duration of a subject's participation in the study will be approximately 13 months.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with bilateral cataracts and planned bilateral cataract extraction by routine phacoemulsification.
  • Potential postoperative BCDVA of 0.2 logMAR or better in each eye in the expert medical opinion of the investigator.
  • Astigmatism suitable for correction with available toric IOL models.
  • Other protocol-specified inclusion criteria may apply.

排除标准

  • Age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and other eye conditions as specified in the protocol.
  • Moderate to severe dry eye that would affect study measurements.
  • Other protocol-specified exclusion criteria may apply.

研究组 & 干预措施

Clareon TruPlus Monofocal IOL

Experimental

Implantation with the Clareon TruPlus Monofocal IOL (Non-Toric or Toric) following removal of the clouded natural lens using phacoemulsification

干预措施: Clareon TruPlus Monofocal Non-Toric IOL (Device)

Clareon TruPlus Monofocal IOL

Experimental

Implantation with the Clareon TruPlus Monofocal IOL (Non-Toric or Toric) following removal of the clouded natural lens using phacoemulsification

干预措施: Clareon TruPlus Monofocal Toric IOL (Device)

Clareon TruPlus Monofocal IOL

Experimental

Implantation with the Clareon TruPlus Monofocal IOL (Non-Toric or Toric) following removal of the clouded natural lens using phacoemulsification

干预措施: Phacoemulsification (Procedure)

结局指标

主要结局

Mean Binocular Photopic Best Corrected Distance Visual Acuity (BCDVA)

时间窗: Day 0 preoperative, Month 1, Month 3, Month 12

Visual acuity (VA) will be assessed binocularly (both eyes together) with correction in place under photopic (well-lit) conditions at a distance of 4 meters. BCDVA will be measured using letter charts and recorded in logarithm of the Minimum Angle of Resolution (logMAR). The LogMAR VA scale ranges from -0.30 (20/10 Snellen) to 1.00 (20/200 Snellen). A LogMAR value of 0 equates to 20/20 Snellen VA (normal distance eyesight), with negative LogMAR values representing better than 20/20 VA. Subjects with at least one implanted eye with a toric IOL will be categorized as toric as specified in the statistical analysis plan. No hypothesis testing is pre-specified for this endpoint

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验

进行中(未招募)
1 期
A study to learn more about how safe the study treatment finerenone is in long-term use when taken with an ACE inhibitor or angiotensin receptor blocker over 18 months of use in children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuriaTreatment of children with chronic kidney disease and proteinuriaMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.1Level: PTClassification code 10037032Term: ProteinuriaSystem Organ Class: 10038359 - Renal and urinary disorders
EUCTR2021-002905-89-GRBayer AG100
进行中(未招募)
1 期
A study to learn more about how safe the study treatment finerenone is in long-term use when taken with an ACE inhibitor or angiotensin receptor blocker over 18 months of use in children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuriaTreatment of children with chronic kidney disease and proteinuriaMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.1Level: PTClassification code 10037032Term: ProteinuriaSystem Organ Class: 10038359 - Renal and urinary disorders
EUCTR2021-002905-89-FIBayer AG100
尚未招募
3 期
An 18-month, open-label, single-arm safety extension study of an age-and bodyweight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuriachronic kidney disease
NL-OMON56223Bayer2
进行中(未招募)
1 期
A study to learn more about how safe the study treatment finerenone is in long-term use when taken with an ACE inhibitor or angiotensin receptor blocker over 18 months of use in children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuriaTreatment of children with chronic kidney disease and proteinuriaMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.1Level: PTClassification code 10037032Term: ProteinuriaSystem Organ Class: 10038359 - Renal and urinary disorders
EUCTR2021-002905-89-DEBayer AG100
进行中(未招募)
1 期
A study to learn more about how safe the study treatment finerenone is in long-term use when taken with an ACE inhibitor or angiotensin receptor blocker over 18 months of use in children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuriaTreatment of children with chronic kidney disease and proteinuriaMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.1Level: PTClassification code 10037032Term: ProteinuriaSystem Organ Class: 10038359 - Renal and urinary disorders
EUCTR2021-002905-89-PTBayer AG100